Fate Therapeutics to present CAR T-cell portfolio at ACR Convergence 2026
Fate Therapeutics says it has been selected for four presentations highlighting its off-the-shelf CAR T-cell portfolio in autoimmune disease at ACR Convergence 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.